{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:07:33Z","timestamp":1790806053580,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1IK2BX006111-01A1"],"award-info":[{"award-number":["1IK2BX006111-01A1"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca","award":["ESR 17-13124"],"award-info":[{"award-number":["ESR 17-13124"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL157261"],"award-info":[{"award-number":["R01HL157261"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL157261"],"award-info":[{"award-number":["R01HL157261"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outcomes via beneficial effects on systemic and cardiac inflammation and cardiac fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research and design methods<\/jats:title>\n                    <jats:p>This randomized placebo-controlled clinical trial enrolled 62 adult patients (mean age 62, 17% female) with type 2 diabetes (T2D) without known heart failure. Subjects were randomized to 12 months of daily 10\u00a0mg dapagliflozin or placebo. For all patients, blood\/plasma samples and cardiac magnetic resonance imaging (CMRI) were obtained at time of randomization and at the end of 12 months. Systemic inflammation was assessed by plasma IL-1B, TNF\u03b1, IL-6 and ketone levels and PBMC mitochondrial respiration, an emerging marker of sterile inflammation. Global myocardial strain was assessed by feature tracking; cardiac fibrosis was assessed by T1 mapping to calculate extracellular volume fraction (ECV); and cardiac tissue inflammation was assessed by T2 mapping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between the baseline and 12-month time point, plasma IL-1B was reduced (\u2212 1.8 pg\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003) while ketones were increased (0.26 mM,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0001) in patients randomized to dapagliflozin. PBMC maximal oxygen consumption rate (OCR) decreased over the 12-month period in the placebo group but did not change in patients receiving dapagliflozin (\u2212 158.9 pmole\/min\/10\n                      <jats:sup>6<\/jats:sup>\n                      cells,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0497 vs. \u2212 5.2 pmole\/min\/10\n                      <jats:sup>6<\/jats:sup>\n                      cells,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.41), a finding consistent with an anti-inflammatory effect of SGLT2i. Global myocardial strain, ECV and T2 relaxation time did not change in both study groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial.gov Registration<\/jats:title>\n                    <jats:p>NCT03782259.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-024-02294-z","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T12:02:30Z","timestamp":1717761750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure"],"prefix":"10.1186","volume":"23","author":[{"given":"Dennis D.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Naumova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Isquith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Sapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Balu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Voronyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baocheng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ordovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"issue":"22","key":"2294_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"2294_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, et al. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"6","key":"2294_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of Cardiovascular benefits of Sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"key":"2294_CR4","doi-asserted-by":"publisher","first-page":"1008922","DOI":"10.3389\/fcvm.2022.1008922","volume":"9","author":"L Scisciola","year":"2022","unstructured":"Scisciola L, et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials. Front Cardiovasc Med. 2022;9:1008922.","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"2294_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"2294_CR6","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127.","journal-title":"Nat Commun"},{"issue":"6","key":"2294_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1021312027486","volume":"3","author":"RR de Souza","year":"2002","unstructured":"de Souza RR. Aging of myocardial collagen. Biogerontology. 2002;3(6):325\u201335.","journal-title":"Biogerontology"},{"issue":"14","key":"2294_CR8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","volume":"131","author":"MR Zile","year":"2015","unstructured":"Zile MR, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131(14):1247\u201359.","journal-title":"Circulation"},{"issue":"4","key":"2294_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jacc.2005.09.050","volume":"47","author":"J Asbun","year":"2006","unstructured":"Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. 2006;47(4):693\u2013700.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2294_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jcmg.2015.11.005","volume":"9","author":"AJ Taylor","year":"2016","unstructured":"Taylor AJ, et al. T1 mapping: basic techniques and clinical applications. JACC Cardiovasc Imaging. 2016;9(1):67\u201381.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2294_CR11","doi-asserted-by":"publisher","first-page":"44937","DOI":"10.1038\/srep44937","volume":"7","author":"M Zeng","year":"2017","unstructured":"Zeng M, et al. The Association between diffuse myocardial fibrosis on Cardiac magnetic resonance T1 mapping and myocardial dysfunction in Diabetic rabbits. Sci Rep. 2017;7:44937.","journal-title":"Sci Rep"},{"issue":"6","key":"2294_CR12","doi-asserted-by":"publisher","first-page":"e003073","DOI":"10.1161\/CIRCIMAGING.114.003073","volume":"8","author":"S Bohnen","year":"2015","unstructured":"Bohnen S, et al. Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging. 2015;8(6):e003073.","journal-title":"Circ Cardiovasc Imaging."},{"issue":"11","key":"2294_CR13","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1172\/JCI138538","volume":"130","author":"B Zhou","year":"2020","unstructured":"Zhou B, et al. Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure. J Clin Invest. 2020;130(11):6054\u201363.","journal-title":"J Clin Invest"},{"issue":"1","key":"2294_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12968-014-0069-x","volume":"16","author":"D Dabir","year":"2014","unstructured":"Dabir D, et al. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2014;16(1):69.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"2294_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1120\/jacmp.v17i5.6237","volume":"17","author":"J Jung","year":"2016","unstructured":"Jung J, et al. Patient-specific 17-segment myocardial modeling on a bull\u2019s eye map. J Appl Clin Med Phys. 2016;17(5):453\u201365.","journal-title":"J Appl Clin Med Phys"},{"issue":"1","key":"2294_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","volume":"66","author":"BC Lupsa","year":"2023","unstructured":"Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia. 2023;66(1):23\u201332.","journal-title":"Diabetologia"},{"issue":"12","key":"2294_CR17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jacbts.2022.06.012","volume":"7","author":"DD Wang","year":"2022","unstructured":"Wang DD, et al. Safety and Tolerability of Nicotinamide Riboside in Heart failure with reduced ejection fraction. JACC Basic Transl Sci. 2022;7(12):1183\u201396.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"2294_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1161\/CIRCRESAHA.116.307974","volume":"119","author":"VO Puntmann","year":"2016","unstructured":"Puntmann VO, et al. T1 mapping in characterizing myocardial disease: a Comprehensive Review. Circ Res. 2016;119(2):277\u201399.","journal-title":"Circ Res"},{"issue":"1","key":"2294_CR19","doi-asserted-by":"publisher","first-page":"15348","DOI":"10.1038\/s41598-019-51949-5","volume":"9","author":"JC Hsu","year":"2019","unstructured":"Hsu JC, et al. Effect of Empagliflozin on Cardiac function, adiposity, and diffuse fibrosis in patients with type 2 diabetes Mellitus. Sci Rep. 2019;9(1):15348.","journal-title":"Sci Rep"},{"issue":"3","key":"2294_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00005-009-0024-y","volume":"57","author":"M Bujak","year":"2009","unstructured":"Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz). 2009;57(3):165\u201376.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"3","key":"2294_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1084\/jem.183.3.949","volume":"183","author":"A Kumar","year":"1996","unstructured":"Kumar A, et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183(3):949\u201358.","journal-title":"J Exp Med"},{"issue":"6","key":"2294_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ejheart.2003.11.014","volume":"6","author":"RP Dai","year":"2004","unstructured":"Dai RP, et al. Differential expression of cytokines in the rat heart in response to sustained volume overload. Eur J Heart Fail. 2004;6(6):693\u2013703.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2294_CR23","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/jcsm.12763","volume":"12","author":"K Busch","year":"2021","unstructured":"Busch K, et al. Inhibition of the NLRP3\/IL-1beta axis protects against sepsis-induced cardiomyopathy. J Cachexia Sarcopenia Muscle. 2021;12(6):1653\u201368.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2294_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fphar.2017.00363","volume":"8","author":"C Peiro","year":"2017","unstructured":"Peiro C, et al. IL-1beta inhibition in Cardiovascular complications Associated to Diabetes Mellitus. Front Pharmacol. 2017;8:363.","journal-title":"Front Pharmacol"},{"issue":"10","key":"2294_CR25","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","volume":"111","author":"A Abbate","year":"2013","unstructured":"Abbate A, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394\u2013400.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2294_CR26","first-page":"169","volume":"91","author":"PM Rommens","year":"1991","unstructured":"Rommens PM, Goffin J. [Osteosynthesis of the dens axis fracture]. Acta Chir Belg. 1991;91(4):169\u201374.","journal-title":"Acta Chir Belg"},{"issue":"9","key":"2294_CR27","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","volume":"126","author":"A Abbate","year":"2020","unstructured":"Abbate A, et al. Interleukin-1 and the Inflammasome as therapeutic targets in Cardiovascular Disease. Circ Res. 2020;126(9):1260\u201380.","journal-title":"Circ Res"},{"issue":"9","key":"2294_CR28","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1681\/ASN.2016101101","volume":"28","author":"SG Coca","year":"2017","unstructured":"Coca SG, et al. Plasma biomarkers and kidney function decline in early and established Diabetic kidney disease. J Am Soc Nephrol. 2017;28(9):2786\u201393.","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"2294_CR29","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1042\/CS20171459","volume":"132","author":"JC Jha","year":"2018","unstructured":"Jha JC, et al. A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clin Sci (Lond). 2018;132(16):1811\u201336.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"2294_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12902-023-01512-1","volume":"23","author":"S Gohari","year":"2023","unstructured":"Gohari S, et al. The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials. BMC Endocr Disord. 2023;23(1):257.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2294_CR31","doi-asserted-by":"publisher","first-page":"14709","DOI":"10.1038\/s41598-019-51298-3","volume":"9","author":"R Shirakawa","year":"2019","unstructured":"Shirakawa R, et al. Mitochondrial reactive oxygen species generation in blood cells is associated with disease severity and exercise intolerance in heart failure patients. Sci Rep. 2019;9(1):14709.","journal-title":"Sci Rep"},{"key":"2294_CR32","doi-asserted-by":"publisher","first-page":"10229","DOI":"10.1038\/srep10229","volume":"5","author":"P Li","year":"2015","unstructured":"Li P, et al. Mitochondrial respiratory dysfunctions of blood mononuclear cells link with cardiac disturbance in patients with early-stage heart failure. Sci Rep. 2015;5:10229.","journal-title":"Sci Rep"},{"issue":"9","key":"2294_CR33","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1172\/JCI120845","volume":"128","author":"MN Sack","year":"2018","unstructured":"Sack MN. Mitochondrial fidelity and metabolic agility control immune cell fate and function. J Clin Invest. 2018;128(9):3651\u201361.","journal-title":"J Clin Invest"},{"issue":"12","key":"2294_CR34","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1172\/JCI83260","volume":"125","author":"J Traba","year":"2015","unstructured":"Traba J, et al. Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. J Clin Invest. 2015;125(12):4592\u2013600.","journal-title":"J Clin Invest"},{"key":"2294_CR35","doi-asserted-by":"crossref","unstructured":"Julla JB, et al. Blood monocyte phenotype is a marker of Cardiovascular Risk in Type 2 diabetes. Circ Res; 2023.","DOI":"10.1161\/CIRCRESAHA.123.322757"},{"issue":"5","key":"2294_CR36","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ehf2.12505","volume":"6","author":"NSR Lan","year":"2019","unstructured":"Lan NSR, et al. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019;6(5):927\u201335.","journal-title":"ESC Heart Fail"},{"issue":"16","key":"2294_CR37","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","volume":"70","author":"C Grani","year":"2017","unstructured":"Grani C, et al. Prognostic value of Cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017;70(16):1964\u201376.","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02294-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02294-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02294-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T12:06:14Z","timestamp":1717761974000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02294-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2294"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02294-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4132581\/v1","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"19 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"a. The trial was approved by the Institutional Review Board at the University of Washington.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"b. All authors approve the manuscript and give their consent for submission and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"197"}}